Showing papers on "Lucinactant published in 2004"
TL;DR: Surfaxin is significantly more efficacious than Exosurf in the prevention of RDS and in reducing RDS-related mortality through 14 days after birth.
Abstract: Background: Animal-derived, protein-containing surfactants perform better vs. non–protein-containing surfactants for the prevention and treatment of Respiratory Distress Syndrome (RDS). A new generation, non–animal-derived surfactant, Surfaxin, containing a peptide that mimics human SP-B, appears effective in animals and in early studies of infants with RDS.1 Our objective was to compare the efficacy and safety of Surfaxin vs. Exosurf in the prevention of RDS.
3 citations
TL;DR: Combined data from these trials show lower all-cause mortality with Surfaxin than with the animal-derived surfactants (combined results of Survanta and Curosurf), consistent with the hypothesis that both the presence of, and a higher concentration of, surfactant protein amplify the benefits of surfACTant therapy.
Abstract: Background: Animal-derived, protein-containing surfactants perform better vs. non–protein-containing surfactants for prevention and treatment of Respiratory Distress Syndrome (RDS). A new generation, non–animal-derived surfactant, Surfaxin, containing a peptide that mimics the action of human SP-B, has been shown to be effective in animals, in studies of infants with RDS,1 and in large, controlled studies in the prevention of RDS in preterm infants. Our objective was to compare the incidence of all-cause mortality at Days 14 and 28, and at 36 weeks postconceptional age of Surfaxin vs. Survanta and Surfaxin vs. Curosurf across two clinical trials measuring their respective safety and efficacy in the prevention of RDS.
2 citations